Register: Design, Build, and Encapsulate: Transforming Digital Sequences into High-Quality, Ready-to-Test mRNA

Date: Wednesday, October 15, 2025 11am–12pm EDT
Event Location: Virtual

This webinar, tailored for scientists in academia, biotech, and pharma, will explore how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy. Join Davide De Lucrezia, Vice President and General Manager at Officinae Bio, and Chunping Xu, Senior Director of Chemistry R&D, TriLink BioTechnologies, as they share strategies, insights, and data on how leveraging machine learning, a novel design platform, and innovation in chemistry can help you increase your probability of success moving high-performing mRNA candidate sequence from concept through to the clinic.

Learning objectives:

• Understand how to leverage AI/machine learning and a novel design platform to optimize mRNA design parameters
• How to apply holistic strategies for mRNA optimization through chemical modifications from cap to tail and mRNA quality improvement through enzyme optimization
  

Davide De Lucrezia

Vice President & General Manager | Officinae Bio (Maravai LifeSciences)

Davide is a synthetic biologist by training with a passion for bridging biology and computer science. He is co-founder and General Manager of Officinae Bio, now part of Maravai Life Sciences. Over the years, he has led multiple biotech ventures, focusing on innovation at the intersection between artificial intelligence and synthetic biology. His mission is to empower biologists to reprogram biology through smarter tools and streamlined workflows.

Chunping Xu

Senior Director of Chemistry R&D | TriLink BioTechnologies

Chunping Xu, PhD, is the Senior Director of Chemistry R&D at TriLink Biotechnologies, where she oversees the development of novel CleanCap® analogs for improved protein expression and process optimization for modified NTPs. In addition, she and her team are investigating how to increase mRNA stability with various chemical modifications. Leveraging expertise in nucleotide chemistry, Dr. Xu and her team have created a library of over 100 novel cap analogs to identify next-generation CleanCap® analogs. Before joining TriLink, she had extensive experience in small molecule drug development and conjugation. 

Lori Ellis

Head of Insights | BioSpace

Lori is the head of insights at BioSpace. She analyzes and comments on industry trends for BioSpace and clients. She creates engaging content for clients to support their marketing objectives. She has been part of an award-winning marketing team and has won a Muse Creative award, a Vega award and several Adobe awards in collaborative team projects for her audio narration work. Her experience in the television/film and audio industries benefits both BioSpace and partners through her moderation and hosting of live and virtual events. While she has covered all elements of the drug development process, her primary focuses are women’s health issues, the economic climate, and the ever-evolving impact of technology – specifically artificial intelligence – on the pharmaceutical industry.